These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28859328)

  • 1. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study.
    Rose T; Grützkau A; Klotsche J; Enghard P; Flechsig A; Keller J; Riemekasten G; Radbruch A; Burmester GR; Dörner T; Hiepe F; Biesen R
    Rheumatology (Oxford); 2017 Sep; 56(9):1618-1626. PubMed ID: 28859328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
    Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis.
    Bizzaro N; Villalta D; Giavarina D; Tozzoli R
    Autoimmun Rev; 2012 Dec; 12(2):97-106. PubMed ID: 22810055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus.
    Biesen R; Dähnrich C; Rosemann A; Barkhudarova F; Rose T; Jakob O; Bruns A; Backhaus M; Stöcker W; Burmester GR; Schlumberger W; Egerer K; Hiepe F
    Arthritis Res Ther; 2011 Feb; 13(1):R26. PubMed ID: 21329504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
    Bauer JW; Petri M; Batliwalla FM; Koeuth T; Wilson J; Slattery C; Panoskaltsis-Mortari A; Gregersen PK; Behrens TW; Baechler EC
    Arthritis Rheum; 2009 Oct; 60(10):3098-107. PubMed ID: 19790071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus.
    Li T; Prokopec SD; Morrison S; Lou W; Reich H; Gladman D; Urowitz M; Scholey J; Fortin PR; Boutros PC; Wither J; Landolt-Marticorena C
    Rheumatology (Oxford); 2015 Mar; 54(3):449-57. PubMed ID: 25193804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus.
    Stuckrad SLV; Klotsche J; Biesen R; Lieber M; Thumfart J; Meisel C; Unterwalder N; Kallinich T
    Lupus; 2020 Dec; 29(14):1914-1925. PubMed ID: 33081587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus.
    Mirioğlu Ş; Çinar S; Uludağ Ö; Gürel E; Varelci S; Özlük Y; Kiliçaslan I; Yalçinkaya Y; Yazici H; Gül A; Inanç M; Artim Esen B
    Turk J Med Sci; 2024; 54(2):391-400. PubMed ID: 39050398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease.
    de Leeuw K; Bungener L; Roozendaal C; Bootsma H; Stegeman CA
    Rheumatology (Oxford); 2017 May; 56(5):698-703. PubMed ID: 28053277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.
    Biesen R; Demir C; Barkhudarova F; Grün JR; Steinbrich-Zöllner M; Backhaus M; Häupl T; Rudwaleit M; Riemekasten G; Radbruch A; Hiepe F; Burmester GR; Grützkau A
    Arthritis Rheum; 2008 Apr; 58(4):1136-45. PubMed ID: 18383365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus.
    Su Y; Jia RL; Han L; Li ZG
    Clin Immunol; 2007 Jan; 122(1):115-20. PubMed ID: 17085075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
    Lisney AR; Szelinski F; Reiter K; Burmester GR; Rose T; Dörner T
    Ann Rheum Dis; 2017 Aug; 76(8):1476-1480. PubMed ID: 28501799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of cut-off value for autoantibodies against double-stranded DNA-complexed nucleosomes based on enzyme linked immunosorbent assay].
    Ohnuma K; Hayashi N; Fukuzumi N; Saito A; Tanaka M; Kumagai S; Kawano S
    Rinsho Byori; 2014 Mar; 62(3):223-30. PubMed ID: 24800496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α.
    Mathian A; Mouries-Martin S; Dorgham K; Devilliers H; Barnabei L; Ben Salah E; Cohen-Aubart F; Garrido Castillo L; Haroche J; Hie M; Pineton de Chambrun M; Miyara M; Sterlin D; Pha M; Lê Thi Huong D; Rieux-Laucat F; Rozenberg F; Gorochov G; Amoura Z
    Arthritis Rheumatol; 2019 May; 71(5):756-765. PubMed ID: 30507062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
    Fayed A; El Menyawi MM; Ghanema M; Shaker O; Elgohary R
    Reumatismo; 2020 Nov; 72(3):145-153. PubMed ID: 33213127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.
    Kong KO; Tan AW; Thong BY; Lian TY; Cheng YK; Teh CL; Koh ET; Chng HH; Law WG; Lau TC; Leong KP; Leung BP; Howe HS
    Clin Exp Immunol; 2009 Apr; 156(1):134-40. PubMed ID: 19175619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.
    Puapatanakul P; Chansritrakul S; Susantitaphong P; Ueaphongsukkit T; Eiam-Ong S; Praditpornsilpa K; Kittanamongkolchai W; Avihingsanon Y
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3.
    Flechsig A; Rose T; Barkhudarova F; Strauss R; Klotsche J; Dähnrich C; Schlumberger W; Enghard P; Burmester GR; Hiepe F; Biesen R
    Clin Exp Rheumatol; 2017; 35(4):598-606. PubMed ID: 28281463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus.
    Zorn-Pauly L; von Stuckrad ASL; Klotsche J; Rose T; Kallinich T; Enghard P; Ostendorf L; Burns M; Doerner T; Meisel C; Schneider U; Unterwalder N; Burmester G; Hiepe F; Alexander T; Biesen R
    Rheumatology (Oxford); 2022 Aug; 61(8):3396-3400. PubMed ID: 34849605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse.
    Mathian A; Mouries-Martin S; Dorgham K; Devilliers H; Yssel H; Garrido Castillo L; Cohen-Aubart F; Haroche J; Hié M; Pineton de Chambrun M; Miyara M; Pha M; Rozenberg F; Gorochov G; Amoura Z
    Ann Rheum Dis; 2019 Dec; 78(12):1669-1676. PubMed ID: 31570366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.